Announced Thu, 6 Aug · 13:39 IST
Q1 FY27 results: revenue up 27 percent, loss narrows to Rs 2.48 cr
Going ConcernRevenue Growth 20pctPat NegativePat Growth 25pctDebt Equity ThresholdResults View source PDFExplain this filing
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.7%1-day move
₹54.10
prior close
₹54.99
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-1.4-1.4-1.4+1.7+3.5+5.2+1.7+2.5+1.7+1.7+4.8——
Up moveDown movePending
AI summary
Krebs Biochemicals posted Q1 FY27 revenue of Rs 6.98 cr, up 27 percent from Rs 5.48 cr YoY. Net loss narrowed to Rs 2.48 cr from Rs 5.32 cr YoY. However, net worth stays deeply negative at minus Rs 162.75 cr. Board approved amalgamation with Ipca Laboratories. Auditor gave an unmodified review report. AP Pollution Control Board closure order remains pending.
Likely market impact
Negative net worth and persistent losses flag going concern risk despite better quarter and proposed Ipca merger.